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Background: Beneficial effects of omega-3 polyunsaturated fatty acids (n-3 PUFAs) on the lipid levels of
dyslipidemic subjects are widely described in the literature. However, the underlying molecular mechanisms are
largely unknown. The aim of this study was to investigate the effects of n-3 PUFAs on the expression of lipid
metabolism-related genes in normo- and dyslipidemic men to unveil potential genes and pathways affecting lipid
metabolism.
Methods: Ten normo- and ten dyslipidemic men were supplemented for twelve weeks with six fish oil capsules
per day, providing 1.14 g docosahexaenoic acid and 1.56 g eicosapentaenoic acid. The gene expression levels were
determined by whole genome microarray analysis and quantitative real-time polymerase chain reaction.
Results: Several transcription factors (peroxisome proliferator-activated receptor α (PPARα), retinoid X receptor (RXR)
α, RXRγ, hepatic nuclear factor (HNF) 6, and HNF1ß) as well as other genes related to triacylglycerol (TG) synthesis
or high-density lipoprotein (HDL-C) and cholesterol metabolism (phospholipids transfer protein, ATP-binding
cassette sub-family G member 5, 2-acylglycerol O-acyltransferase (MOGAT) 3, MOGAT2, diacylglycerol
O-acyltransferase 1, sterol O-acyltransferase 1, apolipoprotein CII, and low-density lipoprotein receptor) were
regulated after n-3 PUFA supplementation, especially in dyslipidemic men.
Conclusion: Gene expression analyses revealed several possible molecular pathways by which n-3 PUFAs lower the
TG level and increase the HDL-C and low-density lipoprotein level, whereupon the regulation of PPARα appear to
play a central role.
Trial registration: ClinicalTrials.gov (ID: NCT01089231)
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Fish oil (FO) and its principal omega-3 polyunsaturated
fatty acids (n-3 PUFAs), eicosapentaenoic acid (EPA,
20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3), have
shown beneficial effects on the lipid profile in numerous
interventional studies [1-3]. Primarily, n-3 PUFAs lower
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reproduction in any medium, provided the orhypertriglyceridemia [4-6]. The TG-lowering effect of n-
3 PUFAs is more pronounced at higher baseline TG
levels [3] and appears to be dose-dependent [1,3]. The
recommended daily intake of n-3 PUFAs for TG lower-
ing in hypertriglyceridemic subjects ranges from 2 to
5 g/d; amounts which could only be reached by supple-
mentation [7,8]. However, moderate n-3 PUFA doses
(1.68 g/d) are similarly efficient at reducing elevated TG
levels in subjects with mild hypertriglyceridemia [9].
Numerous mechanisms have been proposed as con-
tributors to the TG-lowering effect of n-3 PUFAs, for
example, by reducing very low-density lipoprotein-
(VLDL) TG synthesis and secretion from the liver, orl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and chylomicron particles [10]. Beyond TG lowering,
n-3 PUFAs additionally affect the high-density lipopro-
tein cholesterol (HDL-C) metabolism by elevating the
cholesterol-rich HDL2 subtype and reducing the TG-
rich HDL3 subtype [11,12]. Beside these beneficial
effects, studies have repeatedly shown that n-3 PUFAs
increase low-density lipoprotein cholesterol (LDL-C)
levels, which may result from the conversion of VLDL
to LDL-C [13].
The molecular mechanisms by which n-3 PUFAs mod-
ify the lipid metabolism are not completely clarified. The
regulation of gene expression is believed to be a key
mechanism of how n-3 PUFAs mediate their functions.
Specifically, n-3 PUFAs can modulate the activity of sev-
eral transcription factors, such as sterol regulatory
element-binding protein (SREBP) 1 [14], hepatic nuclear
factor (HNF) 4α [15], liver X receptors [16], retinoid X
receptor (RXR) [17], farnesoid X receptor [18], and per-
oxisome proliferator-activated receptors (PPARs) [19],
resulting in an altered expression of corresponding tar-
get genes [20-24]. Although it is known that these genes,
or rather their products, play eminent roles in the regu-
lation of the lipid metabolism, the influence of n-3
PUFAs on a number of additional lipid metabolism-
related genes and involved pathways remain to be dis-
covered. Unravelling these connections may contribute
to the understanding of the molecular mechanisms
explaining the physiological functions of n-3 PUFAs.
The approach of this interventional trial was to moni-
tor gene expression changes in normo- and dyslipidemic
male subjects after n-3 PUFA supplementation using
whole blood samples. With a focus on lipid metabolism-
related genes, we aimed to not only identify genes and
associated pathways that confirm already known
mechanisms, but also to point out alternative mechan-
isms of how n-3 PUFAs affect lipid metabolism.
Methods
This controlled, parallel group intervention study was
conducted at the Institute of Food Science and Human
Nutrition, Leibniz University of Hannover, Germany,
and performed with respect to GCP (Good Clinical
Practice) Guidelines. The approval of the Freiburg Ethics
Commission International (FECI) was received. The
clinical investigation was registered at ClinicalTrials.gov
with the identification number NCT01089231.
Parts of this study have been published recently. In
two other publications, we presented regulated path-
ways, which have been discovered in normo- and dysli-
pidemic male subjects after FO supplementation [25] as
well as regulated antioxidative genes expression [26].
Therefore, selection criteria for the study subjects, the
study design as well as the sample collection for geneexpression analyses and methodical procedure of micro-
array experiments are described elsewhere [26].
Determination of fasting serum lipids and apolipoprotein
B48 concentration
Fasting venous blood samples were collected into BD
VacutainerW Blood Collection Tubes (Becton Dickinson,
Heidelberg, Germany) at baseline (t0) and after twelve
weeks (t12) of supplementation. The plasma lipid levels
were determined by specific enzymatic colour reactions
from an external contract laboratory (LADR, Hannover,
Germany).
Apolipoprotein (Apo) B48 concentration in fasting
serum at baseline and after twelve weeks was deter-
mined in 12 subjects using the Shibayagi human Apo B-
48 enzyme linked immunosorbent assay (ELISA) kit
(Xceltis GmbH, Mannheim, Germany). Analysis was per-
formed in accordance to the manufacturer’s recom-
mended procedures.
Quantitative real-time polymerase chain reaction (qRT-
PCR) and data analysis
In order to quantify the expression levels of selected
genes, equal amounts of cDNA were synthesized using
2.0 μg of purified RNA and M-MLV reverse transcript-
ase (Promega, Mannheim, Germany), as well as random
hexamer (Fermentas, St. Leon-Rot, Germany) and oligo
(dT) primers (Carl Roth, Karlsruhe, Germany). Synthe-
sized cDNA was diluted 1:20 with nuclease-free water
and used for the qRT-PCR together with iQ SYBR Green
Supermix (Bio-Rad Laboratories, Hercules, Ca, USA)
and 5 pmol of both forward and reverse primers. The
sequences for target and reference genes were retrieved
from GenBank and the primers applied were manually
designed with the Primer-BLAST tool of the National
Centre for Biotechnology Information, which is based on
the program Primer3 [27]. The primer sequences used
are listed in Table 1. Glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) and ribosomal protein S2 (RPS2)
were identified as the most stable reference genes by the
freely available algorithm geNorm version 3.5.
Statistics
Statistical analysis of blood lipids was processed with
SPSS software version 17.0 (SPSS Inc., Chicago, IL,
USA). Statistical analyses were based on per protocol
population, defined as subjects completing all visits not
infringing the study protocol. The results are presented
as mean ± SD (Table 2). Statistical analysis of Apo B48
levels was performed with the statistical package R ver-
sion 2.15.0. Differences between t0 and t12 were tested
within groups by paired t-test and differences between
groups were examined by t-test. P-values ≤0.05 were
interpreted as statistically significant.
Table 1 Nucleotide sequences of primers for quantitative real-time polymerase chain reaction
Gene symbol RefSeq_ID Sequences (5’- > 3’)
Target genes Apo C II NM_000483.3 forward GCTCCCCCTTCCCAGTAGCTCT
reverse TTCACTGCTTTATTCCCATGGACCC
LDLR NM_000527.3 forward GGGGCCCTGTGTAGGGGGTT
reverse AAAGTGACACCCATCTCCCAGAAGC
Reference genes GAPDH NM_002046.3 forward AAGGTGGTGAAGCAGGCGTCG
reverse AATGCCAGCCCCAGCGTCAAAG
RPS2 NM_002952.3 forward GCAACTTCGCCAAGGCCACCTT
reverse TGGGTCTTGACGAGGTGGTCAGT
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which were quantified by qRT-PCR, were calculated with
the Gene Expression Macro tool (Bio-Rad), which is based
on the algorithm of geNorm [28]. Firstly, normalization
factors were calculated from the geometric mean of the
reference genes GAPDH and RPS2. Furthermore, the
baseline values of the normolipidemic group were defined
as control values so that relative expression values could
be calculated. Therefore, the baseline samples of the
normolipidemic group are given a value of 1.
Results
Subject characteristics
All subjects completed the study. One normo- and three
dyslipidemic subjects had to be excluded from the ana-
lyses because of low RNA yield (n = 3) and consumption
of medication that led to exclusion (n = 1). Thus, data
were available from nine normolipidemic and seven dys-
lipidemic subjects for each investigation time point.
Age and mean weight at baseline did not show any dif-
ferences between either group. However, the dyslipi-
demic subjects had a significantly higher BMI than the
normolipidemic subjects (28.13 kg/m2 vs. 23.66 kg/m2,
respectively). Subjects of the dyslipidemic group can be
characterised as pre-obese (BMI 25–30), which is,
among others, an underlying cause for dyslipidemia.
Nevertheless, the BMI was not changed by dietary inter-
vention in either of the study groups.Table 2 Serum lipid levels of the normo- and dyslipidemic me
over twelve weeks (t12)
Parameters Normolipidemic (n =
t0
Total cholesterol [mg/dl] 183.33 ± 13.88 a 190
Triacylglycerol [mg/dl] 82.22 ± 37.42 a 63
High-density lipoprotein [mg/dl] 58.67 ± 10.92 65
Low-density lipoprotein [mg/dl] 108.33 ± 13.54 112
LDL-C/HDL-C quotient 1.90 ± 0.37 a 1
a: p < 0.05 (Changes of means at baseline were evaluated between normolipidemic
b: p < 0.05 (Changes of means after twelve weeks of supplementation were evaluat
c: p < 0.05 (Changes between t0 and t12 were evaluated within groups by Student’s
_T: p < 0.1 (trend of significance).Changes of blood lipids and apolipoprotein B48 levels
According to the inclusion criteria, dyslipidemic sub-
jects had significantly higher TC and TG levels as well
as a higher LDL-C/HDL-C ratio at baseline (Table 2).
After twelve weeks of supplementation with FO, the
group differences in TC and TG levels and the LDL-C/
HDL-C ratio remained unaffected and similar to differ-
ences observed at baseline. TG levels decreased both in
normolipidemic (−19.2 mg/dl; -23.34%) and dyslipi-
demic subjects (−99.86 mg/dl, -27.59%). The difference
between both groups was not statistically significant.
The LDL-C level increased significantly after FO sup-
plementation in dyslipidemic subjects (29.6 mg/dl;
20.19%), whereas the effect in normolipidemic subjects
was marginal (4.0 mg/dl; 3.69%). Furthermore, FO sup-
plementation resulted in a significant increase in the
HDL-C levels in dyslipidemic subjects (6.28 mg/dl;
13.69%), whereas the HDL-C increase in normolipi-
demic subjects (7.0 mg/dl; 11.93%) showed a tendency
towards statistical significance.
The protein level of Apo B48 in dyslipidemic sub-
jects at baseline was six times higher compared to nor-
molipidemic subjects (p = 0.053) (Figure 1). After
twelve weeks of FO supplementation, Apo B48 levels
decreased both in normolipidemic (−1.8 μg/ml; -36%)
and dyslipidemic subjects (−32.6 μg/ml; -33%), but
only the decrease of the dyslipidemic subjects showed
a tendency of significance (p = 0.059).n at baseline (t0) and after supplementation with fish oil
9) Dyslipidemic (n = 7)
t12 t0 t12
.56 ± 21.88 b 272.86 ± 67.17 a 278.40 ± 45.21 b
.00 ± 14.09 b 362.00 ± 284.62a 262.14 ± 153.52 b
.67 ± 15.23 c_T 45.86 ± 6.15 52.14 ± 9.84 c
.33 ± 16.88 b 146.60 ± 6.43 176.20 ± 20.56 b c
.80 ± 0.51 b 3.10 ± 0.47 a 3.28 ± 0.89 b
and dyslipidemic subjects by Student’s t-test).
ed between normolipidemic and dyslipidemic subjects by Student’s t-test).
t-test for dependent samples).
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Figure 1 Protein levels of apolipoprotein B48 in normolipidemic and dyslipidemic men. Serum protein levels of apolipoprotein B48 (Apo
B48) was determined by ELISA in normo- and dyslipidemic men before (t0) and after twelve weeks (t12) of fish oil supplementation. Differences
between t0 and t12 protein levels were tested by a paired t-test, and differences between groups at each time point were tested by unpaired
t-test using the statistical package R version 2.15.0.
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genes after n-3 PUFA supplementation
Microarray experiments revealed a transcriptional regu-
lation of several transcription factors after FO supple-
mentation, including PPAR alpha (PPARα), RXR alpha
(RXRα), RXR gamma (RXRγ), HNF6, and HNF1ß
(Table 3). While some transcription factors were simi-
larly regulated in normolipidemic men, the expression
was distinctly more strongly regulated in dyslipidemic
men. Additionally, several genes related to TG synthe-
sis and HDL-C and cholesterol metabolism were regu-
lated in dyslipidemic men (Table 3). More precisely,
the PPAR target gene phospholipid transfer protein
(PLTP), as well as the ATP-binding cassette sub-family
G member 5 (ABCG5) were up-regulated, while 2-
acylglycerol O-acyltransferase 3 (MOGAT3), MOGAT2,
diacylglycerol O-acyltransferase 1 (DGAT1), and sterol
O-acyltransferase 1 (SOAT1) were down-regulated after
FO supplementation in dyslipidemic men.
Gene expression changes of Apo CII and LDL receptor
(LDLR) were quantified by qRT-PCR (Figure 2). The
expression of Apo CII in dyslipidemic subjects at base-
line was three times higher compared to normolipi-
demic subjects (p = 0.05). After twelve weeks of FO
supplementation, the expression of Apo CII was
slightly up-regulated in normolipidemic subjects, and
significantly down-regulated in dyslipidemic subjects
(−57.2%; p = 0.04). The expression of LDLR in normo-
lipidemic subjects at baseline was twice as high com-
pared to dyslipidemic subjects (p = 0.008). After twelve
weeks of FO supplementation, no changes in LDLR
expression were observed in normolipidemic subjects,while dyslipidemic subjects showed a significant down-
regulation in LDLR expression (p = 0.02).
Discussion
The effects of n-3 PUFAs on lipid levels in dyslipidemic
conditions are well-known, however, only a few human
studies investigated the underlying molecular mechan-
isms of gene expression levels in humans. Therefore, we
performed a twelve-week lasting n-3 PUFA supplemen-
tation trial with normo- and dyslipidemic male subjects
aiming to identify possible molecular pathways of n-3
PUFAs in humans.
Parts of this study have been published recently, pre-
senting regulated pathways of the lipid metabolism after
FO supplementation such as fatty acid biosynthesis, fatty
acid elongation in mitochondria, fatty acid metabolism,
glycerolipid metabolism, glycerophospholipid metabol-
ism, arachidonic acid metabolism, linoleic acid metabol-
ism and alpha-linoleic acid metabolism [25]. The present
paper focuses on the influence of n-3 PUFAs on specific
lipid metabolism associated gene expression.
Although the lipid metabolism is mainly located in the
liver, several key regulators of the TG, HDL-C and LDL-
C metabolism were found to be regulated on a transcrip-
tional level in whole blood cells.
TG metabolism
Supplementation of normo- and dyslipidemic subjects
with n-3 PUFAs resulted in a decrease of TG levels by
23 and 28%, which is comparable to other studies [10].
Several genes which are likely to be involved in TG low-
ering were observed to be regulated (Figure 2).
Table 3 Expression ratios of lipid metabolism-related genes
Gene Gene
symbol
Entrez_ID RefSeq_ID dyslipidemic normolipidemic Function
Ratio Ratio Ratio Ratio Ratio Ratio
t4h:t0 t1:t0 t12:t0 t4h:t0 t1:t0 t12:t0
Transcription factors
Peroxisome proliferator-activated
receptor alpha
PPARA 5465 NM_001001928.2 −8.19* 2.72** - - - -
Regulation of the
lipid metabolism
NM_005036.4
Retinoic X receptor RXR-alpha RXRA 6256 NM_002957.4 - −4.50* - 3.14* 3.79*
Retinoic acid receptor RXR-gamma RXRG 6258 NM_006917.3 3.16*** 4.79*** 4.11*** −3.19** - −2.03**
Hepatocyte nuclear factor 6 HNF6 3175 NM_004498.1 −2.27* −4.89* −3.43* - - -
Hepatocyte nuclear factor 1-beta HNF1B 6928 NM_000458.2 - −3.64* −2.56* - - -
Triacylglycerol synthesis
2-acylglycerol O-acyltransferase 3 MOGAT3 346606 NM_178176.2 - −27.07* −3.48* - - -
TG synthesis2-acylglycerol O-acyltransferase 2 MOGAT2 80168 NM_025098.2 −3.08* - - - - -
Diacylglycerol O-acyltransferase 1 DGAT1 8694 NM_012079.4 - −2.67* - - - -
HDL-C metabolism
Phospholipid transfer protein PLTP 5360 NM_006227.2 - 3.30* 4.15* - - - Modify HDL-C
particles sizeNM_182676.1
Cholesterol metabolism
ATP-binding cassette sub-family G
member 5
ABCG5 64240 NM_022436.2 - 4.06* 5.34* - - - Cholesterol efflux
sterol O-acyltransferase 1 SOAT1 6646 NM_003101.4 - −2.45* −2.37** - - - Cholesterol
synthesis
Expression ratios were displayed for genes which were differentially expressed after four hours (t4h), one week (t1) and twelve weeks (t12) of fish oil
supplementation in normolipidemic and dyslipidemic men.
-: no regulation.
*: p = 0.05.
**: p < 0.05.
***: p < 0.01.
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PPARα was up-regulated in dyslipidemic men after one
week of n-3 PUFA supplementation. Transactivation of
PPARs results in a repression of Apo CIII and Apo B,
which, in turn, results in an enhanced lipoprotein lipase0
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Figure 2 Regulatory effects of eicosapentaenoic acid and docosahexa
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in blood cells but in other organs and tissues [32-34].
Two other transcription factors besides PPARα were
regulated after n-3 PUFA supplementation. HNF6 and
HNF1ß were down-regulated in dyslipidemic subjects at
nearly all time-points. HNF6 is associated with several
regulatory pathways influencing glucose metabolism,
cholesterol metabolism, bile acid biosynthesis, as well as
the synthesis and transport of serum carrier proteins
[35]. Synergisms between HNF6 and HNF1α or between
HNF1β and GATA6 could increase the activity of the
HNF4α promoter [36], which, in turn, increases VLDL
secretion. Since Apo CIII and Apo B are target genes of
HNF4α [37], a reduced HNF4α expression, mediated by
a down-regulation of HNF6 and HNF1ß, may reduce the
VLDL secretion; the main TG-lowering effect of n-3
PUFAs. However, expression changes of HNF4α were
not observed after FO supplementation in our experi-
ments, most likely because HNF4α is expressed in liver,
kidney, intestine, and pancreas [38]. Nevertheless, a
robust suppression of the transcriptional HNF4α activity
by n-3 PUFAs has been shown in vitro [39]. Further-
more, it was found that n-3 PUFAs reduce the expres-
sion of HNF4α in rat hepatocytes resulting in a
decreased expression of Apo B and microsomal TG
transfer protein, which suggests a reduced VLDL secre-
tion [15]. Taken together, these findings suggest that this
molecular pathway is a possible mechanism explaining
the TG-lowering effect of n-3 PUFAs.
In addition to transcription factors, the expression of
several other TG metabolism-associated genes was
regulated after n-3 PUFA supplementation. Apo CII
acts as a cofactor for LPL, which hydrolyses TGs in
chylomicrons and VLDL particles to glycerine and free
FAs. Therefore, constant Apo CII levels are crucial for
LPL activation [40], ensuring efficient lipolysis of TG-
rich lipoproteins. Studies have shown that dyslipidemic
subjects without genetic disorders present higher Apo
CII levels (7.0 mg/dl) than normolipidemic subjects
(3.0 mg/dl) [41,42], which results in a disturbance of the
Apo CII/LPL balance. Dyslipidemic subjects of our study
consistently exhibited higher Apo CII mRNA expression
levels than normolipidemic subjects at baseline. After
FO treatment, Apo CII expression was down-regulated
in dyslipidemic men suggesting a re-establishment of the
Apo CII/LPL balance and an increased LPL-mediated
TG clearance. In agreement, Zhang and co-workers [43]
observed reduced plasma Apo CII levels in Chinese
woman after increased fish intake (80 g fatty fish five
times per week) over eight weeks.
Finally, the mRNA expression of three genes involved
in TG synthesis, MOGAT3, MOGAT2 and DGAT1,
were down-regulated in dyslipidemic men after n-3
PUFA supplementation. MOGATs and DGATs are keyenzymes of the monoacylglycerol (MAG) pathway [44],
which is primarily responsible for the re-synthesis of
TGs from FAs and 2-MAG in enterocytes [45-47]. Be-
sides the intestine, MOGAT2 and MOGAT3 are simi-
larly expressed in the liver [44,47], whereas DGAT1 is
expressed ubiquitously [48]. To the best of our know-
ledge, an effect of n-3 PUFAs on the expression of
MOGAT2 and MOGAT3 has not yet been described.
Knockdown of MOGAT3 by siRNA in liver-derived cells
was followed by a reduced enzyme activity [44], which is
accompanied by reduced intestinal dietary fat absorption
in mice [49]. Due to their involvement in TG re-
synthesis and secretion, it is believed that MOGAT2 and
3, but also DGAT1 are potential therapeutic drug targets
for treating diet-induced dyslipidemia and obesity
[44,49-51], whereas an activation of PPARα was sug-
gested as the initial regulator [52]. We assume that the
down-regulation of MOGAT2, MOGAT3 and DGAT1,
observed in whole blood cells after FO supplementation,
will similarly take place in enterocytes or hepatocytes,
resulting in a reduced re-synthesis of TG and thus TG
levels in circulation.
In addition, n-3 PUFA supplementation resulted in a
marked reduction of Apo B48 levels (~30%), which
might support this hypothesis. Apo B48 is an integral
stabilizing component of re-synthesized TG containing
chylomicrons [53]. Patients with hyperlipidemia and
metabolic syndrome show elevated Apo B48 levels
compared to normolipidemic subjects [54,55], which is
connected with a higher cardiovascular risk. A reduced
re-synthesis and secretion of TG in enterocytes would
be accompanied with a reduced formation of chylomi-
crons and associated Apo B48. The lowering effect of
n-3 PUFAs on levels of chylomicrons, their remnants,
as well as Apo B48 has been shown in other studies
[8]. However, beside this indirect effect, n-3 PUFAs
might directly influence the synthesis of Apo B48.
HDL cholesterol metabolism
As expected, FO supplementation increased HDL-C
levels in both normo- and dyslipidemic subjects. The
underlying HDL-C level raising mechanisms are not
completely understood. Another target gene of PPARα
that might be involved in raising HDL-C levels is PLTP
[56-58], which was up-regulated in dyslipidemic subjects
(Figure 3). PLTP can modulate HDL-C size and compos-
ition [59,60] by the transfer of phospholipids from TG-
rich lipoproteins to HDL-C particles [61]. However, in
contrast to our results, incubation of Hep G2 cells with
EPA, DHA or arachidonic acid resulted in a decreased
expression of PLTP [62]. Similarly, results from animal
trials were inconsistent. Both PLTP deficiency and PLTP
overexpression resulted in a significant reduction of
HDL-C levels in the circulation [63].
Figure 3 Transcript levels of target genes in normolipidemic and dyslipidemic men. Transcript levels of apolipoprotein CII (Apo CII) and
low-density lipoprotein receptor (LDLR) was determined by qRT-PCR in normo- and dyslipidemic men before (t0) and after twelve weeks (t12) of
fish oil supplementation. Pooled group samples were used in triplicates. Triplicates were averaged and corrected by two reference genes,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and ribosomal proteine S2 (RPS2). Corrected expressions were compared with baseline
gene expression of normolipidemic subjects and relative expression changes are displayed.
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A well-known effect of FO supplementation is a slight
increase of LDL-C levels after n-3 PUFA supplementa-
tion [5], which is most likely the result of an increased
conversion of VLDL-C to LDL-C [13]. Although we
observed a considerable increase in LDL-C levels in dys-
lipidemic subjects, the expression of several regulated
genes in the same subjects indicate not only cholesterol-
lowering, but also an enhancing effect (Figure 3). LDLR,
which is expressed in nearly all cells, but predominantly
in liver cells, transports cholesterol-rich lipoprotein par-
ticles, preferably LDL-C, via endocytosis into the cell,
resulting in LDL-C clearance [64]. Even though high
cholesterol concentrations inhibit the LDLR expression
[65], LDLR mRNA levels in dyslipidemic subjects were
two times higher compared to normolipidemic subjects.
After FO supplementation, the LDLR expression was
down-regulated in dyslipidemic subjects, which is in
agreement with other studies [66]. The reduced LDLR
expression suggests a diminished LDL-C clearance and
could be another mechanism explaining the n-3 PUFA-
induced rise in LDL-C levels.
In contrast, the regulation of two other factors points
to a cholesterol-lowering effect. The half-transporters
ABCG5 and ABCG8 play a pivotal role in the regulation
of dietary cholesterol transport into the intestinal and
biliary lumen for faecal excretion [67]. The up-
regulation of ABCG5 in dyslipidemic subjects mightinduce a pathway that results in increased cholesterol ef-
flux. In agreement with our results, two animal studies
revealed an increased hepatic ABCG5 and ABCG8 ex-
pression in mice after FO feeding [68,69]. The regulation
might be triggered by PPARA, since PPARα agonists
caused an up-regulation of ABCG5 expression in
hypercholesterolemic subjects [70].
Similarly, the down-regulation of SOAT1, observed in
dyslipidemic subjects after FO supplementation, suggests
a cholesterol-lowering effect. SOATs play important
roles in cellular cholesterol homeostasis in various tis-
sues [71]. Accordingly, a down-regulation of SOAT1 ex-
pression after n-3 PUFA treatment has been observed in
human breast cancer cells [72].
Limitations
The study has a number of potential limitations. As
already mentioned, it is critical to investigate the regula-
tive effect of n-3 PUFAs on the expression of lipid
metabolism-associated genes in whole blood cells in-
stead of liver cells. However, the sampling of biopsies
from the liver in this study was precluded for ethical and
medical reasons. We similarly abstained from isolating
lymphocytes or peripheral blood mononuclear cells
(PBMCs), an approach which was chosen by two other
groups investigating a similar question [73,74], since cell
fractioning steps involve stress-induced alterations in
gene expression profiles [75]. However, many lipid
Schmidt et al. Lipids in Health and Disease 2012, 11:172 Page 8 of 10
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nucleated blood cells: For example, PPARα is expressed
in monocytes, macrophages and lymphocytes [76,77],
while HNF6 and DGAT were found to be expressed in
PBMCs [48,78]. In addition, the pooling of RNA samples
reduces inter-individual variation, enabling one to focus
on the effects of FO supplementation on the population
level in contrast to an individual level [79]. However, the
approach of sample pooling provides several limitations,
primarily the reduction of statistical power.
Conclusion
This pilot study suggests molecular pathways on how
n-3 PUFAs affect lipid metabolism. Although the study
is limited by the usage of whole blood cells obviating
strong conclusions about lipid metabolism, several lipid
metabolism-associated genes were shown to be regu-
lated on a transcriptional level in dyslipidemic subjects,
including transcription factors PPARα, RXRα, RXRγ,
HNF6, and HNF1ß, as well as other lipid regulators,
MOGAT2, MOGAT3, DGAT1, Apo CII, PLTP, LDLR,
ABCG5, and SOAT1. We assume that this transcrip-
tional regulation will equally take place in cells of the
liver or other tissues. Given this assumption, n-3
PUFAs activate several transcription factors resulting
in the regulation of numerous target genes which, in
turn, affect multiple lipid regulators. Accordingly, the
results give indications for (1) decreased TG levels as
a result of an enhanced VLDL catabolism and reduced
VLDL production, as well as a decreased TG re-
synthesis in enterocytes and hepatocytes, while (2)
increased HDL-C levels may be the result of an
increased transfer of phospholipids from TG-rich lipo-
proteins to HDL-C particles. Finally, (3) LDL-C levels
may be influenced in both directions: A decreased
LDL-C clearance may result in rising LDL-C levels, on
the one hand, while an increased cholesterol efflux and
a reduced cholesteryl ester synthesis result in decreasing
LDL-C levels, on the other hand. Future studies com-
bining gene expression, metabolic markers and clinical
end points need to clarify the significance of the
hypothesized molecular mechanisms.
Abbreviations
ABCG5: ATP-binding cassette sub-family G member 5; Apo: Apolipoprotein;
DGAT: Diacylglycerol O-acyltransferase; DHA: Docosahexaenoic acid;
EPA: Eicosapentaenoic acid; FA: Fatty acid; FO: Fish oil;
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; GCP: Good clinical
practice; HDL-C: High-density lipoprotein cholesterol; HNF: Hepatic nuclear
factor; LDL-C: Low-density lipoprotein cholesterol; LDLR: LDL receptor;
LPL: Lipoprotein lipase; MOGAT: 2-acylglycerol O-acyltransferase; n-3
PUFA: Omega-3 polyunsaturated fatty acid; PPAR: Peroxisome proliferator-
activated receptor; PBMC: Peripheral blood mononuclear cells;
PLTP: Phospholipid transfer protein; qRT-PCR: Quantitative real-time
polymerase chain reaction; RPS2: Ribosomal protein S2; RXR: Retinoid X
receptor; SOAT1: Sterol O-acyltransferase 1; SREBP: Sterol regulatory element-
binding protein; t: Time point; TC: Total cholesterol; TG: Triacylglycerol;
VLDL: Very low-density lipoprotein.Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors have read and approved the final manuscript. SS was involved in
the study, experimental design, data analysis, interpretation, and manuscript
writing. The study was mainly performed by SS. FS was involved in the
experimental design and informed advice. KOM was involved in the
experimental design, data analysis and manuscript editing. JPS was involved
in study design, data interpretation and manuscript writing. JW was involved
in manuscript writing. The group leader of the Institute of Technical
Chemistry, TS, was involved in the study design and manuscript editing. The
group leader of the Institute of Food Science and Human Nutrition, AH, was
involved in the study design and manuscript editing. Both JPS and AH were
coordinators of the study.
Acknowledgements
The supply of the study supplements from Dr. Loges + Co. GmbH, Winsen,
Germany, is gratefully acknowledged. Similarly, we thank Philip Saunders
who proofread the manuscript. Most of all, we would like to thank the
participants who contributed their time to this project.
This study was supported by the Federal Ministry of Education and Research,
Germany.
Author details
1Institute of Food Science and Human Nutrition, Faculty of Natural Sciences
at the Leibniz University of Hannover, Am Kleinen Felde 30, Hannover 30167,
Germany. 2Institute of Technical Chemistry, Faculty of Natural Sciences at the
Leibniz University of Hannover, Callinstr. 5, Hannover 30167, Germany.
Received: 11 September 2012 Accepted: 7 December 2012
Published: 14 December 2012
References
1. Harris WS: n-3 fatty acids and lipoproteins: comparison of results from
human and animal studies. Lipids 1996, 3:243–252.
2. Harris WS: n-3 fatty acids and serum lipoproteins: human studies.
Am J Clin Nutr 1997, 65:1645S–1654S.
3. Musa-Veloso K, Binns MA, Kocenas AC, Poon T, Elliot JA, Rice H,
Oppedal-Olsen H, Lloyd H, Lemke S: Long-chain omega-3 fatty acids
eicosapentaenoic acid and docosahexaenoic acid dose-dependently
reduce fasting serum triglycerides. Nutr Rev 2010, 3:155–167.
4. Skulas-Ray AC, West SG, Davidson MH, Kris-Etherton PM: Omega-3 fatty
acid concentrates in the treatment of moderate hypertriglyceridemia.
Expert Opin Pharmacother 2008, 7:1237–1248.
5. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J: Effects of
omega-3 fatty acids on serum markers of cardiovascular disease risk: a
systematic review. Atherosclerosis 2006, 1:19–30.
6. Tremoli E, Eligini S, Colli S, Maderna P, Risè P, Pazzucconi F, Marangoni F,
Sirtori CR, Galli C: n-3 fatty acid ethyl ester administration to healthy
subjects and to hypertriglyceridemic patients reduces tissue factor
activity in adherent monocytes. Arterioscler Thromb 1994, 10:1600–1608.
7. Kris-Etherton PM, Harris WS, Appel LJ: Fish consumption, fish oil, omega-3
fatty acids, and cardiovascular disease. Circulation 2002, 21:2747–2757.
8. Park Y, Harris WS: Omega-3 fatty acid supplementation accelerates
chylomicron triglyceride clearance. J Lipid Res 2003, 3:455–463.
9. Schuchardt JP, Neubronner J, Kressel G, Merkel M, von Schacky C C, Hahn A:
Moderate doses of EPA and DHA from re-esterified triacylglycerols but
not from ethyl-esters lower fasting serum triacylglycerols in statin-
treated dyslipidemic subjects: Results from a six month randomized
controlled trial. Prostaglandins Leukot Essent Fatty Acids 2011, 6:381–386.
10. Shearer GC, Savinova OV, Harris WS: Fish oil - How does it reduce plasma
triglycerides? Biochim Biophys Acta 2012, 5:843–851.
11. Mori TA, Bao DQ, Burke V, Puddey IB, Watts GF, Beilin LJ: Dietary fish as a
major component of a weight-loss diet: effect on serum lipids, glucose,
and insulin metabolism in overweight hypertensive subjects. Am J Clin
Nutr 1999, 5:817–825.
12. Mori TA, Burke V, Puddey IB, Watts GF, O’Neal DN, Best JD, Beilin LJ: Purified
eicosapentaenoic and docosahexaenoic acids have differential effects on
serum lipids and lipoproteins, LDL particle size, glucose, and insulin in
mildly hyperlipidemic men. Am J Clin Nutr 2000, 5:1085–1094.
Schmidt et al. Lipids in Health and Disease 2012, 11:172 Page 9 of 10
http://www.lipidworld.com/content/11/1/17213. Lu G, Windsor SL, Harris WS: Omega-3 fatty acids alter lipoprotein
subfraction distributions and the in vitro conversion of very low
density lipoproteins to low density lipoproteins. J Nutr Biochem 1999,
3:151–158.
14. Caputo M, Zirpoli H, Torino G, Tecce MF: Selective regulation of UGT1A1
and SREBP-1c mRNA expression by docosahexaenoic, eicosapentaenoic,
and arachidonic acids. J Cell Physiol 2011, 1:187–193.
15. López-Soldado I, Avella M, Botham KM: Suppression of VLDL secretion by
cultured hepatocytes incubated with chylomicron remnants enriched in
n-3 polyunsaturated fatty acids is regulated by hepatic nuclear factor-
4alpha. Biochim Biophys Acta 2009, 12:1181–1189.
16. Howell G, Deng X, Yellaturu C, Park EA, Wilcox HG, Raghow R, Elam MB: N-3
polyunsaturated fatty acids suppress insulin-induced SREBP-1c
transcription via reduced trans-activating capacity of LXRalpha.
Biochim Biophys Acta 2009, 12:1190–1196.
17. de Urquiza AM, Liu S, Sjöberg M, Zetterström RH, Griffiths W, Sjövall J,
Perlmann T: Docosahexaenoic acid, a ligand for the retinoid X receptor in
mouse brain. Science 2000, 5499:2140–2144.
18. Zhao A, Yu J, Lew J, Huang L, Wright SD, Cui J: Polyunsaturated fatty acids
are FXR ligands and differentially regulate expression of FXR targets.
DNA Cell Biol 2004, 8:519–526.
19. Oyekan A: PPARs and their effects on the cardiovascular system. Clin Exp
Hypertens 2011, 5:287–293.
20. Clarke SD, Gasperikova D, Nelson C, Lapillonne A, Heird WC: Fatty acid
regulation of gene expression: a genomic explanation for the benefits of
the mediterranean diet. Ann N Y Acad Sci 2002, 967:283–298.
21. Davidson MH: Mechanisms for the hypotriglyceridemic effect of marine
omega-3 fatty acids. Am J Cardiol 2006, 4A:27i–33i.
22. Jump DB, Thelen A, Mater M: Dietary polyunsaturated fatty acids and
hepatic gene expression. Lipids 1999, 34:S209–S212.
23. Price PT, Nelson CM, Clarke SD: Omega-3 polyunsaturated fatty acid
regulation of gene expression. Curr Opin Lipidol 2000, 1:3–7.
24. Vanden Heuvel JP: Cardiovascular disease-related genes and regulation
by diet. Curr Atheroscler Rep 2009, 6:448–455.
25. Schmidt S, Stahl F, Mutz K, Scheper T, Hahn A, Schuchardt JP: Different
gene expression profiles in normo- and dyslipidemic men after fish oil
supplementation: results from a randomized controlled trial. Lipids Health
Dis 2012, 1:105.
26. Schmidt S, Stahl F, Mutz K, Scheper T, Hahn A, Schuchardt JP:
Transcriptome-based identification of antioxidative gene expression
after fish oil supplementation in normo- and dyslipidemic men.
Nutri metabol 2012, 1:45.
27. Rozen S, Skaletsky H: Primer3 on the WWW for general users and for
biologist programmers. Methods Mol Biol 2000, 132:365–386.
28. Vandesompele J, de Preter K, Pattyn F, Poppe B, van Roy N, de Paepe A,
Speleman F: Accurate normalization of real-time quantitative RT-PCR
data by geometric averaging of multiple internal control genes.
Genome Biol 2002, 3. doi:10.1186/gb-2002-3-7-research0034. RESEARCH0034.
29. Forman BM, Chen J, Evans RM: Hypolipidemic drugs, polyunsaturated
fatty acids, and eicosanoids are ligands for peroxisome proliferator-
activated receptors alpha and delta. Proc Natl Acad Sci USA 1997,
9:4312–4317.
30. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS,
Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann JM: Fatty acids
and eicosanoids regulate gene expression through direct interactions
with peroxisome proliferator-activated receptors alpha and gamma.
Proc Natl Acad Sci USA 1997, 9:4318–4323.
31. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC:
Mechanism of action of fibrates on lipid and lipoprotein metabolism.
Circulation 1998, 19:2088–2093.
32. Jong MC, Hofker MH, Havekes LM: Role of ApoCs in lipoprotein
metabolism: functional differences between ApoC1, ApoC2, and ApoC3.
Arterioscler Thromb Vasc Biol 1999, 3:472–484.
33. Knott TJ, Rall SC, Innerarity TL, Jacobson SF, Urdea MS, Levy-Wilson B,
Powell LM, Pease RJ, Eddy R, Nakai H: Human apolipoprotein B: structure
of carboxyl-terminal domains, sites of gene expression, and
chromosomal localization. Science 1985, 4721:37–43.
34. Wang H, Eckel RH: Lipoprotein lipase: from gene to obesity. Am J Physiol
Endocrinol Metab 2009, 2:E271–E288.
35. Wang K, Holterman A: Pathophysiologic role of hepatocyte nuclear factor
6. Cell Signal 2012, 1:9–16.36. Hatzis P, Talianidis I: Regulatory mechanisms controlling human
hepatocyte nuclear factor 4alpha gene expression. Mol Cell Biol 2001,
21:7320–7330.
37. Ladias JA, Hadzopoulou-Cladaras M, Kardassis D, Cardot P, Cheng J, Zannis
V, Cladaras C: Transcriptional regulation of human apolipoprotein genes
ApoB, ApoCIII, and ApoAII by members of the steroid hormone receptor
superfamily HNF-4, ARP-1, EAR-2, and EAR-3. J Biol Chem 1992,
22:15849–15860.
38. Sladek FM: Orphan receptor HNF-4 and liver-specific gene expression.
Receptor 1994, 1:64.
39. Hertz R, Magenheim J, Berman I, Bar-Tana J: Fatty acyl-CoA thioesters are
ligands of hepatic nuclear factor-4alpha. Nature 1998, 6675:512–516.
40. Kei AA, Filippatos TD, Tsimihodimos V, Elisaf MS: A review of the role of
apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease.
Metab Clin Exp 2012, doi:10.1016/j.metabol.2011.12.002.
41. Liu Y, Wang J, Zhang R, Zhang Y, Xu Q, Zhang J, Zhang Y, Zheng Z, Yu X,
Jing H, Nosaka N, Kasai M, Aoyama T, Wu J, Xue C: A good response to oil
with medium- and long-chain fatty acids in body fat and blood lipid
profiles of male hypertriglyceridemic subjects. Asia Pac J Clin Nutr 2009,
3:351–358.
42. Sakurabayashi I, Saito Y, Kita T, Matsuzawa Y, Goto Y: Reference intervals
for serum apolipoproteins A-I, A-II, B, C-II, C-III, and E in healthy Japanese
determined with a commercial immunoturbidimetric assay and effects
of sex, age, smoking, drinking, and Lp(a) level. Clin Chim Acta 2001,
1–2:87–95.
43. Zhang J, Wang C, Li L, Man Q, Meng L, Song P, Frøyland L, Du Z: Dietary
inclusion of salmon, herring and pompano as oily fish reduces CVD risk
markers in dyslipidaemic middle-aged and elderly Chinese women.
Br J Nutr 2012, 6:1–11.
44. Hall AM, Kou K, Chen Z, Pietka TA, Kumar M, Korenblat KM, Lee K, Ahn K,
Fabbrini E, Klein S, Goodwin B, Finck BN: Evidence for regulated
monoacylglycerol acyltransferase expression and activity in human liver.
J Lipid Res 2012, 5:990–999.
45. Cheng D, Nelson TC, Chen J, Walker SG, Wardwell-Swanson J, Meegalla R,
Taub R, Billheimer JT, Ramaker M, Feder JN: Identification of acyl
coenzyme A:monoacylglycerol acyltransferase 3, an intestinal specific
enzyme implicated in dietary fat absorption. J Biol Chem 2003,
16:13611–13614.
46. Hiramine Y, Tanabe T: Characterization of acyl-coenzyme A:diacylglycerol
acyltransferase (DGAT) enzyme of human small intestine. J Physiol
Biochem 2011, 2:259–264.
47. Yen CE, Farese RV: MGAT2, a monoacylglycerol acyltransferase expressed
in the small intestine. J Biol Chem 2003, 20:18532–18537.
48. Cases S, Smith SJ, Zheng YW, Myers HM, Lear SR, Sande E, Novak S, Collins
C, Welch CB, Lusis AJ, Erickson SK, Farese RV: Identification of a gene
encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in
triacylglycerol synthesis. Proc Natl Acad Sci USA 1998, 22:13018–13023.
49. Yen CE, Cheong M, Grueter C, Zhou P, Moriwaki J, Wong JS, Hubbard B,
Marmor S, Farese RV: Deficiency of the intestinal enzyme acyl CoA:
monoacylglycerol acyltransferase-2 protects mice from metabolic
disorders induced by high-fat feeding. Nat Med 2009, 4:442–446.
50. Smith SJ, Cases S, Jensen DR, Chen HC, Sande E, Tow B, Sanan DA, Raber J,
Eckel RH, Farese RV: Obesity resistance and multiple mechanisms of
triglyceride synthesis in mice lacking Dgat. Nat Genet 2000, 1:87–90.
51. Buhman KK, Smith SJ, Stone SJ, Repa JJ, Wong JS, Knapp FF, Burri BJ,
Hamilton RL, Abumrad NA, Farese RV: DGAT1 is not essential for intestinal
triacylglycerol absorption or chylomicron synthesis. J Biol Chem 2002,
28:25474–25479.
52. Berge RK, Madsen L, Vaagenes H, Tronstad KJ, Göttlicher M, Rustan AC: In
contrast with docosahexaenoic acid, eicosapentaenoic acid and
hypolipidaemic derivatives decrease hepatic synthesis and secretion of
triacylglycerol by decreased diacylglycerol acyltransferase activity and
stimulation of fatty acid oxidation. Biochem J 1999, 343(Pt 1):191–197.
53. van Greevenbroek MM, de Bruin TW: Chylomicron synthesis by intestinal
cells in vitro and in vivo. Atherosclerosis 1998, 1:S9–S16.
54. Sakai N, Uchida Y, Ohashi K, Hibuse T, Saika Y, Tomari Y, Kihara S, Hiraoka H,
Nakamura T, Ito S, Yamashita S, Matsuzawa Y: Measurement of fasting
serum apoB-48 levels in normolipidemic and hyperlipidemic subjects by
ELISA. J Lipid Res 2003, 6:1256–1262.
55. Kinoshita M, Ohnishi H, Maeda T, Yoshimura N, Takeoka Y, Yasuda D, Kusano
J, Mashimo Y, Saito S, Shimamoto K, Teramoto T: Increased serum
Schmidt et al. Lipids in Health and Disease 2012, 11:172 Page 10 of 10
http://www.lipidworld.com/content/11/1/172apolipoprotein B48 concentration in patients with metabolic syndrome.
J Atheroscler Thromb 2009, 4:517–522.
56. Bouly M, Masson D, Gross B, Jiang XC, Fievet C, Castro G, Tall AR, Fruchart
JC, Staels B, Lagrost L, Luc G: Induction of the phospholipid transfer
protein gene accounts for the high density lipoprotein enlargement in
mice treated with fenofibrate. J Biol Chem 2001, 28:25841–25847.
57. Lemay DG, Hwang DH: Genome-wide identification of peroxisome
proliferator response elements using integrated computational
genomics. J Lipid Res 2006, 7:1583–1587.
58. Tu AY, Albers JJ: DNA sequences responsible for reduced promoter
activity of human phospholipid transfer protein by fibrate.
Biochem Biophys Res Commun 1999, 3:802–807.
59. Jauhiainen M, Metso J, Pahlman R, Blomqvist S, van Tol A, Ehnholm C:
Human plasma phospholipid transfer protein causes high density
lipoprotein conversion. J Biol Chem 1993, 6:4032–4036.
60. Settasatian N, Duong M, Curtiss LK, Ehnholm C, Jauhiainen M, Huuskonen J,
Rye KA: The mechanism of the remodeling of high density lipoproteins
by phospholipid transfer protein. J Biol Chem 2001, 29:26898–26905.
61. Tall AR, Krumholz S, Olivecrona T, Deckelbaum RJ: Plasma phospholipid
transfer protein enhances transfer and exchange of phospholipids
between very low density lipoproteins and high density lipoproteins
during lipolysis. J Lipid Res 1985, 7:842–851.
62. Kuang Y, Eric Paulson K, Lichtenstein AH, Lamon-Fava S: Regulation of the
expression of key genes involved in HDL metabolism by unsaturated
fatty acids. Br J Nutr 2012, 6:1–9.
63. Yazdanyar A, Yeang C, Jiang X: Role of phospholipid transfer protein in
high-density lipoprotein- mediated reverse cholesterol transport.
Curr Atheroscler Rep 2011, 3:242–248.
64. Brown MS, Goldstein JL: A receptor-mediated pathway for cholesterol
homeostasis. Science 1986, 4746:34–47.
65. Goldstein JL, Brown MS: Molecular medicine. The cholesterol quartet.
Science 2001, 5520:1310–1312.
66. Dawson K, Zhao L, Adkins Y, Vemuri M, Rodriguez RL, Gregg JP, Kelley DS,
Hwang DH: Modulation of blood cell gene expression by DHA
supplementation in hypertriglyceridemic men. J Nutr Biochem 2011,
6:616–621.
67. Yu L, Hammer RE, Li-Hawkins J, von Bergmann K, Lutjohann D, Cohen JC,
Hobbs HH: Disruption of Abcg5 and Abcg8 in mice reveals their crucial
role in biliary cholesterol secretion. Proc Natl Acad Sci USA 2002,
25:16237–16242.
68. Kamisako T, Tanaka Y, Ikeda T, Yamamoto K, Ogawa H: Dietary fish oil
regulates gene expression of cholesterol and bile acid transporters in
mice. Hepatol Res 2012, 3:321–326.
69. Nishimoto T, Pellizzon MA, Aihara M, Stylianou IM, Billheimer JT, Rothblat G,
Rader DJ: Fish oil promotes macrophage reverse cholesterol transport in
mice. Arterioscler Thromb Vasc Biol 2009, 10:1502–1508.
70. Roglans N, Vázquez-Carrera M, Alegret M, Novell F, Zambón D, Ros E,
Laguna JC, Sánchez RM: Fibrates modify the expression of key factors
involved in bile-acid synthesis and biliary-lipid secretion in gallstone
patients. Eur J Clin Pharmacol 2004, 12:855–861.
71. Chang T, Li B, Chang CCY, Urano Y: Acyl-coenzyme A:cholesterol
acyltransferases. Am J Physiol Endocrinol Metab 2009, 1:E1–E9.
72. Hammamieh R, Chakraborty N, Miller S, Waddy E, Barmada M, Das R, Peel
SA, Day AA, Jett M: Differential effects of omega-3 and omega-6 Fatty
acids on gene expression in breast cancer cells. Breast Cancer Res Treat
2007, 1:7–16.
73. Bouwens M, van de Rest O, Dellschaft N, Bromhaar MG, de Groot LCPGM,
Geleijnse JM, Müller M, Afman LA: Fish-oil supplementation induces
antiinflammatory gene expression profiles in human blood mononuclear
cells. Am J Clin Nutr 2009, 2:415–424.
74. Gorjão R, Verlengia R, de Lima TM, Soriano FG, Boaventura MFC, Kanunfre
CC, Peres CM, Sampaio SC, Otton R, Folador A, Martins EF, Curi TCP, Portiolli
EP, Newsholme P, Curi R: Effect of docosahexaenoic acid-rich fish oil
supplementation on human leukocyte function. Clin Nutr 2006, 6:923–938.
75. Vartanian K, Slottke R, Johnstone T, Casale A, Planck SR, Choi D, Smith JR,
Rosenbaum JT, Harrington CA: Gene expression profiling of whole blood:
comparison of target preparation methods for accurate and
reproducible microarray analysis. BMC Genomics 2009, 10:2.
76. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC,
Chapman J, Najib J, Staels B: Activation of proliferator-activated receptorsalpha and gamma induces apoptosis of human monocyte-derived
macrophages. J Biol Chem 1998, 40:25573–25580.
77. Mandard S, Müller M, Kersten S: Peroxisome proliferator-activated
receptor alpha target genes. Cell Mol Life Sci 2004, 4:393–416.
78. Zhao Y, Huang Z, Lazzarini P, Wang Y, Di A, Chen M: A unique human
blood-derived cell population displays high potential for producing
insulin. Biochem Biophys Res Commun 2007, 1:205–211.
79. Kendziorski C, Irizarry RA, Chen K, Haag JD, Gould MN: On the utility of
pooling biological samples in microarray experiments. Proc Natl Acad Sci
USA 2005, 12:4252–4257.
doi:10.1186/1476-511X-11-172
Cite this article as: Schmidt et al.: Regulation of lipid metabolism-related
gene expression in whole blood cells of normo- and dyslipidemic men
after fish oil supplementation. Lipids in Health and Disease 2012 11:172.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
